ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2026
Summary of the National Advisory Committee on Immunization (NACI) Statement: Updated guidance on respiratory syncytial virus (RSV) vaccines for older adults and for adults at high risk of severe RSV disease.
Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Summary of the National Advisory Committee on Immunization (NACI) Statement: Updated guidance on respiratory syncytial virus (RSV) vaccines for older adults and for adults at high risk of severe RSV disease.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Respiratory syncytial virus (RSV) is a common respiratory virus that can have serious complications for older adults and adults with certain medical conditions. Since July 2024, the National Advisory Committee on Immunization (NACI) has provided immunization guidance for the protection of older adults against RSV. In April 2026, NACI updated its guidance to reflect emerging epidemiological data identifying younger adults at high risk of severe RSV and evidence on the benefits of RSV vaccines in older adults and adults at high risk. Methods: NACI reviewed available evidence on the benefits and risks of RSV vaccination in older adults and individuals at higher risk, as well as additional factors, including ethics, equity, feasibility, acceptability and cost-effectiveness. Results: The RSV disease burden in younger adults with certain underlying conditions is comparable to that in older adults. Among older adults, RSV infection may increase the risk of cardiovascular events and Guillain-Barré syndrome (GBS). The RSV vaccines demonstrate strong protection against RSV-associated lower respiratory tract disease and severe outcomes, with favourable safety profiles. Monitoring for rare adverse events following immunization, total duration of protection, and need for boosters is ongoing. Conclusion: NACI expanded the use of RSV vaccines to some adults at high risk for whom the balance of clinical benefits, safety and feasibility is favourable. NACI strongly recommends RSV immunization programs for all adults aged 75 years and older; adults aged 65-74 who are at increased risk of severe RSV disease; and adults aged 18 years and older who reside in chronic care facilities, have received a lung or hematopoietic stem cell transplant, are receiving home or chronic oxygen therapy, or are receiving dialysis. For other adults, vaccination may be considered on an individual basis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.